China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a Series A financing round. The funding was led by 3E Bioventures Capital, with contributions from Tzitzit Asset and Fosun Health Capital. The proceeds will be used for research and development and market construction for multiple percutaneous interventional surgery robots.
Company Background and Technology Platform
Founded three years ago, Würzburg Dynamics boasts a technical platform focusing on 3D reconstruction, surgical planning, intraoperative registration, surgical navigation, and manipulator control. The company describes itself as the only domestic surgical robot company that has mastered the dual technology path based on intraoperative CT and intraoperative ultrasound.
Future Prospects and Strategic Use of Funds
Würzburg Dynamics’ technology platform features strong expandability. In addition to expanding from lung and kidney to other parts of soft tissue percutaneous intervention, it can also expand from percutaneous biopsy, ablation, particle implantation, etc., to natural cavity multi-operation layout. The Series A financing round positions Würzburg Dynamics to further enhance its capabilities in surgical robotics, addressing significant unmet medical needs and contributing to the advancement of minimally invasive surgical procedures.-Fineline Info & Tech
